Ex Vivo Expanded Donor Alloreactive Regulatory T Cells Lose Immunoregulatory, Proliferation, and Antiapoptotic Markers After Infusion Into ATG-lymphodepleted, Nonhuman Primate Heart Allograft Recipients

Supplemental Digital Content is available in the text. Background. Regulatory T cell (Treg) therapy is a promising approach to amelioration of allograft rejection and promotion of organ transplant tolerance. However, the fate of infused Treg, and how this relates to their therapeutic efficacy using different immunosuppressive regimens is poorly understood. Our aim was to analyze the tissue distribution, persistence, replicative activity and phenotypic stability of autologous, donor antigen alloreactive Treg (darTreg) in anti-thymocyte globulin (ATG)-lymphodepleted, heart-allografted cynomolgus monkeys. Methods. darTreg were expanded ex vivo from flow-sorted, circulating Treg using activated donor B cells and infused posttransplant into recipients of major histocompatibility complex-mismatched heart allografts. Fluorochrome-labeled darTreg were identified and characterized in peripheral blood, lymphoid, and nonlymphoid tissues and the graft by flow cytometric analysis. Results. darTreg selectively suppressed autologous T cell responses to donor antigens in vitro. However, following their adoptive transfer after transplantation, graft survival was not prolonged. Early (within 2 wk posttransplant; under ATG, tacrolimus, and anti-IL-6R) or delayed (6–8 wk posttransplant; under rapamycin) darTreg infusion resulted in a rapid decline in transferred darTreg in peripheral blood. Following their early or delayed infusion, labeled cells were evident in lymphoid and nonlymphoid organs and the graft at low percentages (<4% CD4+ T cells). Notably, infused darTreg showed reduced expression of immunoregulatory molecules (Foxp3 and CTLA4), Helios, the proliferative marker Ki67 and antiapoptotic Bcl2, compared with preinfusion darTreg and endogenous CD4+CD25hi Treg. Conclusions. Lack of therapeutic efficacy of infused darTreg in lymphodepleted heart graft recipients appears to reflect loss of a regulatory signature and proliferative and survival capacity shortly after infusion.

[1]  James A. Hutchinson,et al.  Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials , 2020, The Lancet.

[2]  K. Okumura,et al.  A Clinical Trial With Adoptive Transfer of Ex Vivo-induced, Donor-specific Immune-regulatory Cells in Kidney Transplantation—A Second Report , 2020, Transplantation.

[3]  Trent M. Prall,et al.  Characterization of 100 extended major histocompatibility complex haplotypes in Indonesian cynomolgus macaques , 2019, bioRxiv.

[4]  R. Lechler,et al.  Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  B. Hering,et al.  Translational impact of NIH-funded nonhuman primate research in transplantation , 2019, Science Translational Medicine.

[6]  Mihail I Mitov,et al.  mTOR Inhibitor Everolimus in Regulatory T Cell Expansion for Clinical Application in Transplantation , 2019, Transplantation.

[7]  M. Levings,et al.  Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells. , 2019, JCI insight.

[8]  R. Lechler,et al.  IL‐2 therapy preferentially expands adoptively transferred donor‐specific Tregs improving skin allograft survival , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  M. Levings,et al.  Taking regulatory T-cell therapy one step further , 2018, Current opinion in organ transplantation.

[10]  I. Anegon,et al.  Advances on CD8+ Treg Cells and Their Potential in Transplantation. , 2018, Transplantation.

[11]  M. Ansari,et al.  A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants , 2018, Scientific Reports.

[12]  M. Levings,et al.  Guiding regulatory T cells to the allograft , 2017, Current opinion in organ transplantation.

[13]  M. Sarwal,et al.  Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  M. Levings,et al.  Harnessing Advances in T Regulatory Cell Biology for Cellular Therapy in Transplantation , 2017, Transplantation.

[15]  Giovanna Lombardi,et al.  Treg therapy in transplantation: a general overview , 2017, Transplant international : official journal of the European Society for Organ Transplantation.

[16]  F. Vincenti,et al.  Transplant trials with Tregs: perils and promises. , 2017, The Journal of clinical investigation.

[17]  S. Todo,et al.  A pilot study of operational tolerance with a regulatory T‐cell‐based cell therapy in living donor liver transplantation , 2016, Hepatology.

[18]  R. Wiseman,et al.  Regulatory T Cell Infusion Can Enhance Memory T Cell and Alloantibody Responses in Lymphodepleted Nonhuman Primate Heart Allograft Recipients , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  Jeffrey A. Bluestone,et al.  Type 1 diabetes immunotherapy using polyclonal regulatory T cells , 2015, Science Translational Medicine.

[20]  S. Brouard,et al.  Regulatory T Cells in Kidney Transplantation: New Directions? , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  R. Wiseman,et al.  Sequential Monitoring and Stability of Ex Vivo–Expanded Autologous and Nonautologous Regulatory T Cells Following Infusion in Nonhuman Primates , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  A. Thomson,et al.  Generation, cryopreservation, function and in vivo persistence of ex vivo expanded cynomolgus monkey regulatory T cells. , 2015, Cellular immunology.

[23]  M. Levings,et al.  Control of tissue‐localized immune responses by human regulatory T cells , 2015, European journal of immunology.

[24]  A. Kirk,et al.  Superiority of Rapamycin Over Tacrolimus in Preserving Nonhuman Primate Treg Half‐Life and Phenotype After Adoptive Transfer , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  Q. Tang,et al.  Attenuation of Donor‐Reactive T Cells Allows Effective Control of Allograft Rejection Using Regulatory T Cell Therapy , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  M. Atkinson,et al.  Anti-thymocyte globulin (ATG) differentially depletes naïve and memory T cells and permits memory-type regulatory T cells in nonobese diabetic mice , 2012, BMC Immunology.

[27]  K. Wood,et al.  Regulatory immune cells in transplantation , 2012, Nature Reviews Immunology.

[28]  W. Elyaman,et al.  Ex Vivo Expansion of Human Tregs by Rabbit ATG Is Dependent on Intact STAT3‐Signaling in CD4+ T Cells and Requires the Presence of Monocytes , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  A. Nagler,et al.  Anti-T Lymphocyte Globulin (ATG) Induces Generation of Regulatory T Cells, at Least Part of Them Express Activated CD44 , 2012, Journal of Clinical Immunology.

[30]  S. Qi,et al.  Adoptive transfer of CD4+CD25+ regulatory cells combined with low-dose sirolimus and anti-thymocyte globulin delays acute rejection of renal allografts in Cynomolgus monkeys. , 2011, International immunopharmacology.

[31]  J. Wagner,et al.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. , 2011, Blood.

[32]  A. Thomson,et al.  Non-human primate regulatory T cells: current biology and implications for transplantation. , 2010, Transplantation.

[33]  M. Kalos,et al.  Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  R. Jessberger,et al.  Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. , 2009, Immunity.

[35]  P. Munson,et al.  Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. , 2007, Blood.

[36]  L. Turka,et al.  Allograft rejection mediated by memory T cells is resistant to regulation , 2007, Proceedings of the National Academy of Sciences.

[37]  J. Bluestone,et al.  CD4+CD25+ Regulatory T Cells in Transplantation: Progress, Challenges and Prospects , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[38]  David D. Smith,et al.  CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.

[39]  M. Kimikawa,et al.  Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. , 2005, The Journal of clinical investigation.

[40]  M. Roncarolo,et al.  Human Cd25+Cd4+ T Regulatory Cells Suppress Naive and Memory T Cell Proliferation and Can Be Expanded in Vitro without Loss of Function , 2001, The Journal of experimental medicine.

[41]  T. G. S. Wilson,et al.  The Second Report , 1965 .